Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival-Reference-Cited by-同舟云学术

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Published:2016-05-18 Issue: Volume:7 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Facchini Gaetano,Caffo Orazio,Ortega Cinzia,D'Aniello Carmine,Di Napoli Marilena,Cecere Sabrina C.,Della Pepa Chiara,Crispo Anna,Maines Francesca,Ruatta Fiorella,Iovane Gelsomina,Pisconti Salvatore,Montella Maurizio,Berretta Massimiliano,Pignata Sandro,Cavaliere Carla

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference44 articles.

1. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer;Armstrong;Eur. Urol.,2012

2. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature;Armstrong;Oncologist,2009

3. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer;Armstrong;J. Clin. Oncol.,2007a

4. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis;Armstrong;Clin. Cancer Res.,2007b

5. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial;Bahl;Ann. Oncol.,2013

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA;JCO Clinical Cancer Informatics;2024-03

2. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-11-07

3. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2023-06

4. Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate Cancer;2023-04-21

5. Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland;Frontiers in Oncology;2023-04-03